Qualigen Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: AIXC · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1460702

Sentiment: neutral

Topics: corporate-action, filing-update

TL;DR

Qualigen Therapeutics filed an 8-K on Oct 25th regarding shareholder votes and updated office address.

AI Summary

Qualigen Therapeutics, Inc. filed an 8-K on October 29, 2024, reporting on matters submitted to a vote of security holders as of October 25, 2024. The filing indicates a change in the company's principal executive offices to 5857 Owens Avenue, Suite 300, Carlsbad, California 92008. The company was formerly known as Ritter Pharmaceuticals Inc. and was incorporated in Delaware.

Why It Matters

This filing informs investors about important corporate actions and potential changes in the company's operational base, which could impact future business activities and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate actions and office changes, not indicating immediate financial distress or significant operational shifts.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Qualigen Therapeutics' security holders?

The filing states that the report is pursuant to 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals voted upon in this 8-K document.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on October 25, 2024.

What is the new principal executive office address for Qualigen Therapeutics, Inc.?

The new principal executive office address is 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.

What was Qualigen Therapeutics, Inc. formerly known as?

Qualigen Therapeutics, Inc. was formerly known as Ritter Pharmaceuticals Inc.

In which state was Qualigen Therapeutics, Inc. incorporated?

Qualigen Therapeutics, Inc. was incorporated in Delaware.

Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 12.6 · Accepted 2024-10-29 16:05:37

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: October 29, 2024 By: /s/ Kevin A. Richardson II Kevin Richardson II, Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing